A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma.
Nghiemphu P, Omuro A, Cloughesy T, Mellinghoff I, Norden A, Nguyen L, Rajangam K, Wen P. A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma. Journal Of Clinical Oncology 2010, 28: 3085-3085. DOI: 10.1200/jco.2010.28.15_suppl.3085.Peer-Reviewed Original Research